deltatrials
Completed PHASE2 INTERVENTIONAL 6-arm NCT01576718

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Asthma
Interventions Flovent Diskus Fp MDPI Placebo MDPI albuterol/salbutamol
Updated 14 times since 2017 Last updated: May 4, 2018 Started: Apr 30, 2012 Primary completion: Jul 31, 2013 Completion: Oct 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01576718, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 14 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jul 2017 · 2 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~May 2020 · 23 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Jul 2024 · 30 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot~Feb 2026 – present · 2 months · monthly snapshot~Feb 2026 – present · 2 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Feb 2026 — Present [monthly]

    Completed PHASE2

  3. Jan 2026 — Present [monthly]

    Completed PHASE2

  4. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE2

  5. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  2. Jan 2022 — Jul 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jan 2022 [monthly]

    Completed PHASE2

  4. May 2020 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — May 2020 [monthly]

    Completed PHASE2

  6. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

  7. May 2017 — Jul 2017 [monthly]

    Completed PHASE2

  8. Feb 2017 — May 2017 [monthly]

    Completed PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Teva Branded Pharmaceutical Products R&D, Inc.
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Altoona, United States , Aranjuez, Spain , Ashkelon, Israel , Ashland, United States , Athens, Greece , Auckland, New Zealand , Badalona, Spain , Bakersfield, United States and 221 more locations